Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows

ACADIA PHARMACEUTICALS INC

2023-Q3 EPS reported -$0.65 revenue$211,699,000

Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY
Net loss $65.2M ($0.40 per share) vs $27.2M loss YoY; includes $100M upfront for worldwide DAYBUE rights
Full-year 2023 guidance: NUPLAZID net sales $537.5-545M; R&D $340-350M; SG&A $390-400M
Plans to start Phase 3 for ACP-101 (Prader-Willi) and Phase 2/3 for ACP-204 (Alzheimer's psychosis) in Q4 2023
Appoints Albert Kildani as SVP IR and Stephanie Kim as SVP Regulatory Affairs

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $211.7 million, net income $65.2 million, EPS $0.40 per common share. Guidance initiated.

Period: the third quarter ended September 30, 2023
Revenue: $211.7 million
Net income: $65.2 million
EPS: $0.40 per common share
Guidance: initiated
Result: reported results

Exact text from the filing

Total revenues, comprised of net product sales from NUPLAZID and DAYBUE were $211.7 million for the three months ended September 30, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported the nine months ended September 30, 2023 results: revenue $495.4 million, net income $107.1 million, EPS $0.65 per common share. Guidance initiated.

Period: the nine months ended September 30, 2023
Revenue: $495.4 million
Net income: $107.1 million
EPS: $0.65 per common share
Guidance: initiated
Result: reported results

Exact text from the filing

and were $495.4 million for the nine months ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-058254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.